1. Nichols GA, Gullion CM, Koro CE, Ephross SA, Brown JB. The incidence of congestive heart failure in type 2 diabetes: An update. Diabetes Care 2004; 27: 1879 – 1884.
2. MacDonald MR, Petrie MC, Varyani F, Ostergren J, Michelson EL, Young JB, et al. Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: An analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. Eur Heart J 2008; 29: 1377 – 1385.
3. Iribarren C, Karter AJ, Go AS, Ferrara A, Liu JY, Sidney S, et al. Glycemic control and heart failure among adult patients with diabetes. Circulation 2001; 103: 2668 – 2673.
4. Murcia AM, Hennekens CH, Lamas GA, Jiménez-Navarro M, Rouleau JL, Flaker GC, et al. Impact of diabetes on mortality in patients with myocardial infarction and left ventricular dysfunction. Arch Intern Med 2004; 164: 2273 – 2279.
5. Gilbert RE, Krum H. Heart failure in diabetes: Effects of anti- hyperglycaemic drug therapy. Lancet 2015; 385: 2107 – 2117.
6. Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545 – 2559.
7. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 1577 – 1589.
8. Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013; 369: 1317 – 1326.
9. Udell JA, Cavender MA, Bhatt DL, Chatterjee S, Farkouh ME, Scirica BM. Glucose-lowering drugs or strategies and cardiovas- cular outcomes in patients with or at risk for type 2 diabetes: A meta-analysis of randomised controlled trials. Lancet Diabetes Endocrinol 2015; 3: 356 – 366.
10. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015; 373: 2117 – 2128.
11. Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017; 377: 644 – 657.
12. Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2019; 380: 347 – 357.
13. Chilton R, Tikkanen I, Cannon CP, Crowe S, Woerle HJ, Broedl UC, et al. Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes. Diabetes Obes Metab 2015; 17: 1180 – 1193.
14. Neeland IJ, McGuire DK, Chilton R, Crowe S, Lund SS, Woerle HJ, et al. Empagliflozin reduces body weight and indices of adipose distribution in patients with type 2 diabetes mellitus. Diab Vasc Dis Res 2016; 13: 119 – 126.
15. Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Bonaca MP, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: A systematic review and meta-analysis of cardiovascular outcome trials. Lancet 2019; 393: 31 – 39.
16. Takeuchi T, Dohi K, Omori T, Moriwaki K, Sato Y, Nakamori S, et al. Diuretic effects of sodium–glucose cotransporter 2 inhibitor in patients with type 2 diabetes mellitus and heart failure. Int J Cardiol 2015; 201: 1 – 3.
17. Seo Y, Yamamoto M, Machino-Ohtsuka T, Ishizu T, Aonuma K. Effect and safety of sodium glucose cotransporter 2 inhibitors in diabetes patients with drug-refractory advanced heart failure. Circ J 2018; 82: 1959 – 1962.
18. Kurosaki E, Ogasawara H. Ipragliflozin and other sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: Preclinical and clinical data. Pharmacol Ther 2013; 139: 51 – 59.
19. Powell DR, DaCosta CM, Gay J, Ding ZM, Smith M, Greer J, et al. Improved glycemic control in mice lacking Sglt1 and Sglt2. Am J Physiol Endocrinol Metab 2013; 304: E117 – E130.
20. Tahara A, Takasu T, Yokono M, Imamura M, Kurosaki E. Characterization and comparison of sodium-glucose cotrans- porter 2 inhibitors in pharmacokinetics, pharmacodynamics, and pharmacologic effects. J Pharmacol Sci 2016; 130: 159 – 169.
21. Miyata M, Sasaki T, Ikeda Y, Shinsato T, Kubozono T, Furusho Y, et al. Comparative study of therapeutic effects of short- and long-acting loop diuretics in outpatients with chronic heart failure (COLD-CHF). J Cardiol 2012; 59: 352 – 358.
22. Yoshida J, Yamamoto K, Mano T, Sakata Y, Nishio M, Ohtani T, et al. Different effects of long- and short-acting loop diuretics on survival rate in Dahl high-salt heart failure model rats. Cardiovasc Res 2005; 68: 118 – 127.
23. Cohn JN, Levine TB, Olivari MT, Garberg V, Lura D, Francis GS, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984; 311: 819 – 823.
24. Joho S, Akabane T, Ushijima R, Hirai T, Kinugawa K. Sympa- thetic nerve activity efferent drive and beta-blocker treatment: Effect of interaction in systolic heart failure. Circ J 2016; 80: 2149 – 2154.
25. Heise T, Jordan J, Wanner C, Heer M, Macha S, Mattheus M, et al. Acute pharmacodynamic effects of empagliflozin with and without diuretic agents in patients with type 2 diabetes mellitus. Clin Ther 2016; 38: 2248 – 2264.
26. Verbrugge EH. Role of SGLT2 inhibitors in patients with diabetes mellitus and heart failure. Curr Heart Fail Rep 2017; 14: 275 – 283.
27. Rådholm K, Figtree G, Perkovic V, Solomon SD, Mahaffey KW, de Zeeuw D, et al. Canagliflozin and heart failure in type 2 diabetes mellitus: Results from the CANVAS Program (Canagliflozin Cardiovascular Assessment Study). Circulation 2018; 138: 458 – 468.
28. Jordan J, Tank J, Heusser K, Heise T, Wanner C, Heer M, et al. The effect of empagliflozin on muscle sympathetic nerve activity in patients with type II diabetes mellitus. J Am Soc Hypertens 2017; 11: 604 – 612.